(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2010 (10.09.2010)

PCT

(10) International Publication Number
WO 2010/102175 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2010/026315

(22) International Filing Date:
5 March 2010 (05.03.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/209,471	5 March 2009 (05.03.2009)	US
61/209,390	5 March 2009 (05.03.2009)	US

(71) Applicants *(for all designated States except US)*: **MEDAREX, INC.** [US/US]; Route 206 & Province Line Rd., Princeton, NJ 08540 (US). **OXFORD BIOTHERAPEUTICS LTD** [GB/GB]; Willow Court, 7 West Way, Botley, Oxford Oxfordshire OX2 0JB (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TERRETT, Jonathan, Alexander** [GB/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US). **LEBLANC, Heidi** [CA/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US). **HUANG, Haichun** [US/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US). **MEADDOUGH, Erika** [US/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US). **PAN, Chin** [US/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US). **CHEN, Bingliang** [US/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US). **RAO-NAIK, Chetana** [US/US]; Medarex, Inc., 521 Cottonwood Drive, Milpitas, CA 95035 (US).

(74) Agents: **REMILLARD, Jane, E.** et al.; LAHIVE & COCKFIELD, LLP, One Post Office Square, Bocton, MA 02109-2127 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/102175 A1

(54) **Title**: FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1

(57) **Abstract**: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.